Addiction and mental health treatment-focused biotechnology company Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) is building on its psychedelics-as-a-medicine research through a collaborative partnership LOI that would see Mydecine supply two psychedelic drug compounds for mental health treatments in compliance with the standards for Health Canada’s Special Access Program (“SAP”).
The partnership LOI between Mydecine and The Newly Institute Inc. aims to provide more effective responses to psychotherapy patients at The Newly’s private inter-disciplinary mental health clinics across Canada, with a proposed revenue-sharing agreement between the two companies.
Under the rubric of the program, Mydecine will provide cGMP (Current Good Manufacturing Practice-adherent) psilocybin and 3,4-methylenedioxymethamphetamine (known commonly as MDMA, or Ecstasy) along with safety and efficacy data required by the SAP. The Newly will provide the clinic locations and their experienced therapists for the treatments.
“Research supports that psychedelic-assisted psychotherapy can break down deeply rooted psychological defenses, facilitate therapeutic breakthroughs and effect substantial improvements in long-term mental health,” The Newly Chief Scientific Officer Dr. Marshall Ross stated in a news release announcing the LOI (https://ibn.fm/7q7zP).
“Our goal at The Newly is to build a network of clinics across Canada that deliver innovative and leading-edge mental health treatments to individuals in need,” The Newly President & CEO Arthur H. Kwan added. “The platform we’re developing can be very effective in enabling us to deploy new and innovative best-practice treatments and therapies. We are pleased to partner with a company like Mydecine to enhance the mental health care being provided to Canadians.”
The partnership is the first to be announced under Mydecine’s Special Access Support and Supply Program (“SASSP”), which will provide psychedelic drug products and related services to physicians, clinics and hospitals in Canada for psychotherapy (https://ibn.fm/f9Dpl) in the wake of Health Canada’s announcement that federal regulations have been amended to allow caregivers and pharmacists to obtain and prescribe psilocybin and MDMA for treatment-resistant patients (https://ibn.fm/VDTtd).
Mydecine and The Newly will work together to develop the protocols for treatment and therapy manuals for a variety of conditions.
As a company committed to research, development and acceptance of alternative nature-sourced medicine for mainstream use, Mydecine has conducted significant research on the pharmacological potential in mushrooms, discovering dozens of compounds in varied mushroom species — a large majority of which appear to have never been reported before.
“Most of these compounds are evolved to protect the mushroom’s fruiting body from predation by insects, nematodes and bacteria and are complex and metabolically expensive to produce. Since these compounds are evolved to affect biological systems and aspects of metabolic pathways, they stand a higher chance of proving to be useful pharmaceuticals,” the company’s Senior Scientist Duff Sloley stated last year (https://ibn.fm/mI0ab).
A major area of focus for the company’s research has related to treating nicotine-addicted patients in the United States to help them quit smoking (https://ibn.fm/GIPzx), with a proposed FDA-approved study set to launch in the next couple months (https://ibn.fm/QlRsN).
For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
HeartBeam is developing a portable, credit-card-sized device and proprietary software capable of capturing heart signals…
While immunotherapy has scored a significant level of success in treating many types of cancer,…
FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…
Lawmakers in the U.S. Congress hit a stalemate in talks to keep the government open…
In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare…
Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients…